Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Your Article Summary
See Latest ArticlesA Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer
Clinical Cancer Research, 11/06/09
Munster PN et al. – Administration of a single supratherapeutic dose of the histone deacetylase inhibitor vorinostat is not associated with prolongation of the QTc interval. A dedicated QTc study in advanced cancer patients is a robust means for assessing risk for ventricular repolarization prolongation.
Related Articles
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma
Cancer Science, 10/26/09
Relevance Score: 89%
Molecular Targets in Malignant Pleural Mesothelioma Treatment
Current Drug Targets, 11/10/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of a Solitary Bone Metastasis to the Tibia from Colorectal Cancer
Case Reports in Gastroenterology, 11/24/09
Serum Thyroid-Stimulating Hormone Concentration and Morbidity from Cardiovascular Disease and Fractures in Patients on Long-Term Thyroxine Therapy
Journal of Clinical Endocrinology and Metabolism, 11/24/09
Adult Cyclic Vomiting Syndrome Successfully Treated with Intranasal Sumatriptan
Journal of General Internal Medicine, 11/24/09
Sponsor
Article Search
Sponsor
Sponsor